1H. Bonkhoff,U. Stein,K. Remberger. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate[J] 1993,Virchows Archiv A Pathological Anatomy and Histopathology(4):291～294
4Mucci NR, Akdas G, Manely S, et al. Neuroendocrine expression in metastatic prostate cancer:evaluation of high throughput tissue microarrays to detect heterogeneous protein expression[J]. Hum Pathol, 2000, 31(4): 406-414.
5Taneja TK, Sharma SK. Markers olc small cell lung cancer[J]. World J Surg Oncol, 2004, 2: 10.
6Abrahamsson PA, Falkmer S, Falt K, et al. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker" [J]. Pathol Res Pract, 1989, 185(3): 373-380.
7Berruti A, Dogliotti L, Mosca A, et al. Circulating neuroendocrine markers in patients with prostate carcinoma[J]. Cancer, 2000, 88(11): 2590-2597.
8Autorino R, Lamendola MG, De Luca G, et al. Neuroendocrine immunophenotype as predictor of clinical recurrence in 110 patients with prostate cancer[J].Int J Immunopathol Pharmacol, 2007, 20(4): 765-770.
9Bostwick DG, Grignon DJ, Hammond ME, et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999[J]. Arch Pathol Lab Med, 2000, 124(7) : 995-1000.
10Molinie V, Baumert H. New markers in prostate biopsies[J]. Actas Urol Esp, 2007, 31(9): 1(109-1024.
